Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder

seekingalpha2022-02-07

The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

ppyys
2022-02-07
ppyys
Comment and like
MC8989
2022-02-07
MC8989
Good
Betterjob
2022-02-07
Betterjob
Good news
- indietro_:
  Ok
ping23
2022-02-07
ping23
pls like
MandyLow118
2022-02-07
MandyLow118
tq for sharing....
RChia
2022-02-07
RChia
Like please

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2209378762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-07 18:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2209378762","market":"us","top_or_hot":-1,"title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","media":"seekingalpha","content":"<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","article_id":"2209378762","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","pubTimestamp":1644231186,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药"},"translate_title":"赛诺菲的Enjaymo获得美国FDA罕见血液疾病批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9},"content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9098754648,"gmtCreate":1644242478589,"gmtModify":1676533903211,"author":{"id":"3581756384979769","authorId":"3581756384979769","name":"ppyys","avatar":"https://static.tigerbbs.com/610302822a164d13f68b36645cef259a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581756384979769","authorIdStr":"3581756384979769"},"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098754648","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098763926,"gmtCreate":1644235064482,"gmtModify":1676533902284,"author":{"id":"3562482274169298","authorId":"3562482274169298","name":"MC8989","avatar":"https://static.tigerbbs.com/58eed81f9dc051542d8569ad3065f505","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562482274169298","authorIdStr":"3562482274169298"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098763926","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":633526654,"gmtCreate":1644233120905,"gmtModify":1676532687768,"author":{"id":"4087549167151930","authorId":"4087549167151930","name":"Betterjob","avatar":"https://static.tigerbbs.com/3a6e660c283e305dd2a1669316c2511b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087549167151930","authorIdStr":"4087549167151930"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/633526654","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7233629,"gmtCreate":1644234252474,"gmtModify":1663239753726,"authorId":3586255748151463,"author":{"id":3586255748151463,"idStr":"3586255748151463","authorId":3586255748151463,"name":"indietro_","avatar":"https://static.tigerbbs.com/caebb6c2a70cbd2db563a3808f3d7b22","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633526654,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":9098781076,"gmtCreate":1644232408174,"gmtModify":1676533902061,"author":{"id":"3574521189147374","authorId":"3574521189147374","name":"ping23","avatar":"https://static.tigerbbs.com/c38fda829a130d716804cbae538a7cb8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574521189147374","authorIdStr":"3574521189147374"},"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098781076","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098789368,"gmtCreate":1644231978177,"gmtModify":1676533902027,"author":{"id":"4088156876983060","authorId":"4088156876983060","name":"MandyLow118","avatar":"https://static.tigerbbs.com/4f2481989f5fe021a34d2e24b5102138","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088156876983060","authorIdStr":"4088156876983060"},"htmlText":"tq for sharing....","listText":"tq for sharing....","text":"tq for sharing....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098789368","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098780512,"gmtCreate":1644231818004,"gmtModify":1676533902011,"author":{"id":"3576295472948618","authorId":"3576295472948618","name":"RChia","avatar":"https://static.tigerbbs.com/cea89db323c5328650526772cf80ec19","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576295472948618","authorIdStr":"3576295472948618"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098780512","repostId":2209378762,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":66,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2209378762"}